T/NK cell tumor
Conditions
Interventions
Experimental group:Chidamide Tablets
Sponsors
Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Definite diagnosis of T/NK cell tumors: mainly including PTCL, T-ALL, ENKTL, ATLL, T-LGLL, CTCL, ANKL, T-LBL, and other types that the investigator considers appropriate for the study; 2. Receiving allo-HSCT; 3. Tumor assessment of PR and above within 2 months after transplantation; 4. Hematopoietic recovery within 60 days of transplantation; 5. Patient aged 18 to 65 years; 6. ECOG score 60; 7. estimated survival time >=3 months; 8. Agree to participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled active infection or persistent fever within 14 days before enrollment; 2. Significant history of cardiovascular and cerebrovascular diseases or events; history of mental illness; incapacity or limited ability; 3. Uncontrolled concomitant diseases, including but not limited to symptomatic heart failure, uncontrolled hypertension, unstable angina pectoris, active peptic ulcer or bleeding disorders; 4. Patients with long-term drug abuse, alcoholism so as to affect the evaluation of the test results; 5. Pregnant or lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 6. Patients less than 6 weeks after major organ surgery; 7. Abnormal liver function (total bilirubin > 1.5 times the normal value, ALT/AST > 3 times the normal value), abnormal renal function (serum creatinine > 3 times the normal value); 8. Patients are participating in other clinical trials, or plan to start the study treatment less than 1 month from the end of the previous clinical study treatment; 9. The researchers determine that they are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Two-year Cumulative Relapse Rate in Patients Receiving Maintenance Cedaramide Following Allo-HSCT for T/NK-Cell Tumors; | — |
Countries
China
Contacts
Public ContactXiao Yi
Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed